People taking antidepressants at the time of a traumatic brain injury (TBI) do not face a higher risk of serious short-term complications, according to new research published online on January 28 in the journal Neurology.

The nationwide study, led by Dr. Jussi P. Posti of Turku University Hospital in Finland, examined whether antidepressant use before injury affects early outcomes following TBI. Researchers analysed health records of adults aged 16 and older who were admitted with traumatic brain injuries across Finland between 2005 and 2018.

Of the 54,876 patients included in the study, about 14.3 per cent were taking antidepressant medications at the time of their injury. The team assessed whether pre-injury antidepressant use—along with the type of antidepressant and its serotonergic profile—was linked to 30-day mortality, the need for acute neurosurgical operations, or length of hospital stay.

The findings showed no significant difference in 30-day mortality between patients who were using antidepressants and those who were not. After adjusting for other risk factors, antidepressant use was not associated with an increased risk of death within the first month following injury. The researchers also found no meaningful differences based on the type of antidepressant or its effect on serotonin levels.

Interestingly, patients taking antidepressants were slightly less likely to require emergency neurosurgical procedures compared with non-users. However, there was no difference between the two groups in terms of how long they remained hospitalized.

The study also examined whether antidepressant use influenced the known risks associated with vitamin K antagonists, a class of blood-thinning medications. The analysis showed that antidepressant use did not alter the relationship between these drugs and increased mortality or surgical intervention.

“These findings provide reassurance for people who take antidepressants that antidepressant use does not appear to worsen early recovery after traumatic brain injury,” Dr. Posti said in a statement. He added that further research is needed to determine whether the same holds true for long-term recovery and in healthcare systems beyond Finland.

The authors noted that some contributors to the study disclosed ties to the pharmaceutical industry.